To follow today … GUERBET – Capital.fr

(AOF) – Guerbet announces the approval of a new indication for Lipiodol Ultra-Fluid in Denmark for the chemoembolization (cTACE) of tumors in adults with mid-stage hepatocellular carcinoma. Hepatocellular carcinoma is the primary tumor of the most common liver cancer and is the fourth leading cause of cancer-related death in the world each year.

Lipiodol Ultra-Fluid is used in the cTACE, a minimally invasive procedure that consists of mixing Lipiodol Ultra-Fluid with an anti-cancer agent and injecting this mixture into the liver via the trans-arterial route as targeted locoregional chemotherapy for non-hepatic tumors. resectable. Lipiodol Ultra-Fluid acts as both a contrast medium, a vehicle, an anti-cancer drug eluent and a transient vascular embolization agent.

The approval obtained in Denmark demonstrates Guerbet's commitment to invest in innovating and improving the effectiveness of minimally invasive techniques in oncology.

AOF – LEARN MORE

Pharmacy – Health

In 2018, mergers and acquisitions in the sector were close to $ 200 billion, a significant increase over 2017. And 2019 begins strongly with the recovery by Bristol-Myers Squibb (BMS) of biotech specialist Celgene of oncology, for 74 billion dollars. Together, they give birth to a giant with $ 33.3 billion in sales, the world leader in oncology (62% of its turnover) and in cardiovascular diseases.

Acquisitions are multiplying in biotechnology in response to the need of "Big Pharma" to renew their products. More than 71% of drugs in clinical development last year are from biotech, according to the American trade union, BIO. The Japanese Takeda has acquired the Irish Shire, for 81.7 billion dollars. For its part, Eli Lilly bought the biotech Loxo Oncology for $ 8 billion, just after GSK got hold of another American biotech, Tesaro.